Compare Pfizer with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs CADILA HEALTHCARE - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER CADILA HEALTHCARE PFIZER/
CADILA HEALTHCARE
 
P/E (TTM) x 33.4 14.5 231.1% View Chart
P/BV x 5.6 2.8 198.6% View Chart
Dividend Yield % 0.6 1.5 41.9%  

Financials

 PFIZER   CADILA HEALTHCARE
EQUITY SHARE DATA
    PFIZER
Mar-18
CADILA HEALTHCARE
Mar-18
PFIZER/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,365558 423.8%   
Low Rs1,625362 449.5%   
Sales per share (Unadj.) Rs430.3116.3 370.0%  
Earnings per share (Unadj.) Rs78.717.9 440.5%  
Cash flow per share (Unadj.) Rs93.223.1 402.9%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %1.00.8 131.7%  
Book value per share (Unadj.) Rs586.585.4 686.6%  
Shares outstanding (eoy) m45.751,023.74 4.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.0 117.3%   
Avg P/E ratio x25.325.7 98.5%  
P/CF ratio (eoy) x21.419.9 107.7%  
Price / Book Value ratio x3.45.4 63.2%  
Dividend payout %25.419.6 129.7%   
Avg Mkt Cap Rs m91,271470,664 19.4%   
No. of employees `0002.611.8 22.3%   
Total wages/salary Rs m3,14318,545 16.9%   
Avg. sales/employee Rs Th7,484.810,072.7 74.3%   
Avg. wages/employee Rs Th1,195.01,569.1 76.2%   
Avg. net profit/employee Rs Th1,369.11,547.7 88.5%   
INCOME DATA
Net Sales Rs m19,685119,049 16.5%  
Other income Rs m1,1431,132 101.0%   
Total revenues Rs m20,828120,181 17.3%   
Gross profit Rs m5,00328,475 17.6%  
Depreciation Rs m6635,388 12.3%   
Interest Rs m4911 0.5%   
Profit before tax Rs m5,47923,308 23.5%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8785,644 33.3%   
Profit after tax Rs m3,60118,292 19.7%  
Gross profit margin %25.423.9 106.3%  
Effective tax rate %34.324.2 141.6%   
Net profit margin %18.315.4 119.0%  
BALANCE SHEET DATA
Current assets Rs m24,16782,005 29.5%   
Current liabilities Rs m9,54460,720 15.7%   
Net working cap to sales %74.317.9 415.5%  
Current ratio x2.51.4 187.5%  
Inventory Days Days5573 75.3%  
Debtors Days Days2998 29.2%  
Net fixed assets Rs m9,51483,703 11.4%   
Share capital Rs m4581,024 44.7%   
"Free" reserves Rs m26,37586,421 30.5%   
Net worth Rs m26,83287,445 30.7%   
Long term debt Rs m2525,551 0.1%   
Total assets Rs m36,900180,653 20.4%  
Interest coverage x1,305.526.6 4,910.8%   
Debt to equity ratio x00.3 0.3%  
Sales to assets ratio x0.50.7 81.0%   
Return on assets %9.810.6 91.9%  
Return on equity %13.420.9 64.2%  
Return on capital %20.422.0 92.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2242,683 0.1%   
Fx outflow Rs m1,48911,242 13.2%   
Net fx Rs m-1,46631,441 -4.7%   
CASH FLOW
From Operations Rs m3,3189,193 36.1%  
From Investments Rs m-2,383-9,737 24.5%  
From Financial Activity Rs m-1,104515 -214.3%  
Net Cashflow Rs m-169-29 581.0%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.3 90.4%  
FIIs % 4.9 5.9 83.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 11.0 215.5%  
Shareholders   85,207 44,069 193.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS